American Oncology Network (AONC) Looks Fully Priced Following Cencora’s $2.4b Bid
Cencora (COR) has agreed to buy the remaining 96% of American Oncology Network (OTCPK:AONC) it does not already own in a deal valuing AON at US$2.4b.
American Oncology Network’s share price has surged in recent weeks, with a 7 day share price return of 100% and a 30 day move of the same magnitude, while the 1 year total shareholder return of 144.44% and 3 year total shareholder return of 263.64% point to strong momentum that this Cencora bid now crystallises.
Scan beyond American Oncology Network and see how other healthcare operators with strong fundamentals are reacting to deal activity by reviewing our curated list of solid balance sheet and fundamentals (26 results).
After American Oncology Network’s surge on Cencora’s US$2.4b bid, the choice is blunt. Pay up now on the deal terms being signalled, or hold back and risk missing any remaining upside.
American Oncology Network’s valuation signals are blurred by limited data
With American Oncology Network now in play at a US$2.4b headline price and the stock last closing at $22.00, many investors would normally look to standard valuation tools or forward forecasts for clarity. This time, the toolkit is thin, which makes the bid terms and recent share price reaction even more central to the story.
The usual checks on earnings quality, revenue trends and margin direction do not add much structure because there is insufficient recent financial data. The latest reports are more than a year old, there are no analyst price targets in the inputs, and there is no usable discounted cash flow output for American Oncology Network from the SWS DCF model based on the information provided.
That limited visibility runs through a number of metrics. There is not enough data to say whether revenue is expected to grow faster than the wider US market or at a rate above 20% a year. Profit trends over both the past year and the past five years are also unclear, and there is no confirmation yet that American Oncology Network has high quality earnings or improving profit margins.
The return profile looks very different. American Oncology Network has delivered a 1 year total shareholder return of 144.44%, which is ahead of both the US market at 12.7% and the US Healthcare sector at 17.1% over the same period. That outperformance, combined with a 3 year total shareholder return of 263.64%, explains why the current $22.00 price and the deal valuation now carry so much weight in shaping expectations.
Balance sheet structure is another angle to watch. AONC is not a bank and reports no customer deposits, and 100% of its liabilities are from higher risk sources of funding such as external borrowing. That kind of funding mix can be more sensitive to interest costs and refinancing conditions, which matters for a healthcare services group that relies on consistent cash generation from its oncology management operations.
On governance, the signals are mixed. The board is considered experienced with an average director tenure of 3.1 years, and 67% of directors are independent, which points to a reasonable level of oversight. At the same time, American Oncology Network has not appointed any new directors over the last 3 years, so board refresh has been limited and there is not enough information to judge how well leadership incentives are aligned because CEO compensation cannot be compared to peers or to performance with the data available.
Management tenure looks reasonably established, with the leadership team averaging 4 years at the company, which can help continuity as Cencora moves to take full control. Yet return on equity is reported as 0% with the firm currently unprofitable, so investors who remain focused on AONC ahead of deal completion are working with a mix of strong share price momentum, limited recent financial disclosure and a funding base that leans entirely on higher risk liabilities.
With so many gaps in the usual valuation and forecast checks for American Oncology Network, it becomes even more important to benchmark this situation against other healthcare operators that pair solid fundamentals with clearer reporting and lower balance sheet risk. That is where a focused screen on resilient financial profiles can help you frame the Cencora bid premium against better documented alternatives that share a similar operating backdrop.
Still, American Oncology Network’s reliance on higher risk funding sources and limited recent financial disclosure could quickly unsettle sentiment if the deal terms shift or the timing slips.
Find out about the key risks to this American Oncology Network narrative.
Next Steps
Unsettled by how mixed the American Oncology Network story feels right now and how much hinges on Cencora’s offer terms and timing. Act quickly, review the underlying data, and decide whether the flagged issues change your stance by taking a closer look at the 1 important warning sign.
Looking for more investment ideas beyond American Oncology Network?
If Cencora’s move has sharpened your focus on healthcare, use this momentum to refresh your watchlist with other opportunities that have clearer data and different risk profiles.
- Target potential value gaps by scanning companies that combine solid fundamentals with appealing pricing using our focused 29 high quality undervalued stocks.
- Strengthen your income stream by zeroing in on resilient payers highlighted in our carefully filtered 6 dividend fortresses.
- Dial down risk in your portfolio by concentrating on financially robust businesses identified through the curated 30 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com